Validation of the CaReQoL asthma: a patient reported outcome measure for monitoring the perceived effects of pulmonary rehabilitation in adult patients with severe refractory asthma.
| Title: | Validation of the CaReQoL asthma: a patient reported outcome measure for monitoring the perceived effects of pulmonary rehabilitation in adult patients with severe refractory asthma. |
|---|---|
| Authors: | Springvloet L; Nivel, Netherlands Institute for Health Services Research, PO Box 1568, 3500 BN, Utrecht, The Netherlands.; Triemstra M; Nivel, Netherlands Institute for Health Services Research, PO Box 1568, 3500 BN, Utrecht, The Netherlands.; Knottnerus B; Nivel, Netherlands Institute for Health Services Research, PO Box 1568, 3500 BN, Utrecht, The Netherlands.; Rolink M; Nivel, Netherlands Institute for Health Services Research, PO Box 1568, 3500 BN, Utrecht, The Netherlands.; Heijerman H; Department of Respiratory Medicine, University Medical Center Utrecht, Utrecht, The Netherlands.; de Boer D; Nivel, Netherlands Institute for Health Services Research, PO Box 1568, 3500 BN, Utrecht, The Netherlands. D.deBoer@nivel.nl. |
| Source: | Respiratory research [Respir Res] 2023 Jan 13; Vol. 24 (1), pp. 14. Date of Electronic Publication: 2023 Jan 13. |
| Publication Type: | Journal Article |
| Language: | English |
| Journal Info: | Publisher: BioMed Central Ltd Country of Publication: England NLM ID: 101090633 Publication Model: Electronic Cited Medium: Internet ISSN: 1465-993X (Electronic) Linking ISSN: 14659921 NLM ISO Abbreviation: Respir Res Subsets: MEDLINE |
| Imprint Name(s): | Publication: 2001- : London : BioMed Central Ltd.; Original Publication: London : Current Science Ltd., c2000- |
| MeSH Terms: | Asthma*/diagnosis ; Asthma*/drug therapy ; Quality of Life*; Humans ; Adult ; Reproducibility of Results ; Retrospective Studies ; Psychometrics ; Surveys and Questionnaires ; Patient Reported Outcome Measures |
| Abstract: | Background: The CaReQoL Asthma assesses the care-related quality of life outcomes of pulmonary rehabilitation retrospectively in patients with severe asthma. The questionnaire comprises five domains (physical functioning; social functioning; coping with asthma; knowledge about asthma; medication).; Aim: To investigate construct and criterion validity of the CaReQoL Asthma, as well as its responsiveness and minimal important change (MIC), in comparison with other health measures (AQLQ, ACQ and FEV1).; Methods: Eighty three adults with severe refractory asthma filled out the CaReQoL Asthma at 6 and 12 months after a 12-week personalized multidisciplinary pulmonary rehabilitation program in a tertiary asthma centre, either in Switzerland or The Netherlands. Construct validity and responsiveness were assessed by testing pre-defined hypotheses about associations with changes in AQLQ, ACQ and FEV1 scores. Criterion validity and MIC was assessed using Global Perceived Effect (GPE). Factor analyses, Cronbach's alpha, Spearman's correlations, paired t-tests and Student-Newman-Keuls tests were performed.; Results: Cronbach's alphas of the questionnaire domains ranged from 0.82 to 0.95. Good construct validity and responsiveness were found; 84% of the assessed correlations confirm pre-defined hypotheses and reflect both weak and moderate to strong correlations. Good criterion validity was also identified, with CaReQol scores discriminating better than other health measures between levels of GPE at 6 months post-rehabilitation. The MIC for the total score was estimated at 0.84.; Conclusion: These study results suggest that the CaReQoL Asthma is a valid and responsive instrument and shows to be a comprehensive and tailored questionnaire for evaluating and monitoring outcomes of pulmonary rehabilitation in patients with severe refractory asthma. In order to further substantiate the reliability and validity of the CaReQoL Asthma, as well as to monitor outcomes of pulmonary rehabilitation in patients with severe asthma, it is recommended to use the CaReQoL Asthma in addition to other disease specific instruments.; (© 2023. The Author(s).) |
| References: | Thorax. 1992 Feb;47(2):76-83. (PMID: 1549827); Allergy. 2019 Mar;74(3):628-630. (PMID: 30428132); J Asthma Allergy. 2017 Mar 07;10:47-56. (PMID: 28331347); Respir Med. 2005 May;99(5):553-8. (PMID: 15823451); Respir Med. 2020 Sep;171:106123. (PMID: 32846334); Eur Respir J. 2014 Feb;43(2):343-73. (PMID: 24337046); J Clin Epidemiol. 2010 Jul;63(7):760-766.e1. (PMID: 20056385); J Clin Epidemiol. 2007 Jan;60(1):34-42. (PMID: 17161752); J Clin Epidemiol. 1994 Jan;47(1):81-7. (PMID: 8283197); J Allergy Clin Immunol Pract. 2016 Jan-Feb;4(1):130-41. (PMID: 26563672); Health Expect. 2017 Feb;20(1):11-23. (PMID: 26889874); Chest. 1999 May;115(5):1265-70. (PMID: 10334138); BMJ. 2013 Jan 28;346:f167. (PMID: 23358487); Eur Respir J. 1999 Oct;14(4):902-7. (PMID: 10573240); Qual Life Res. 2015 Mar;24(3):631-9. (PMID: 25201169); Cochrane Database Syst Rev. 2017 Mar 13;3:CD012286. (PMID: 28288272); J Allergy Clin Immunol. 2015 Apr;135(4):896-902. (PMID: 25441637); Am J Respir Crit Care Med. 2013 Oct 15;188(8):e13-64. (PMID: 24127811); Health Qual Life Outcomes. 2020 May 27;18(1):157. (PMID: 32460896); Respirology. 2019 Sep;24(9):828-829. (PMID: 30806003); BMC Pulm Med. 2019 Jul 24;19(1):134. (PMID: 31340793); Respirology. 2019 Sep;24(9):916-917. (PMID: 31307112); Eur Respir J. 2012 Dec;40(6):1324-43. (PMID: 22743675); Qual Life Res. 2003 Jun;12(4):349-62. (PMID: 12797708); Health Qual Life Outcomes. 2010 Jul 10;8:65. (PMID: 20618978) |
| Contributed Indexing: | Keywords: Asthma; Patient reported outcome measurement (PROM); Pulmonary rehabilitation; Responsiveness; Validity |
| Entry Date(s): | Date Created: 20230113 Date Completed: 20230117 Latest Revision: 20230117 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC9837900 |
| DOI: | 10.1186/s12931-022-02281-6 |
| PMID: | 36639773 |
| Database: | MEDLINE |
Journal Article